Why does GLP-1 treatment raise gallbladder risk?

Two factors appear to drive it, and they compound each other. Rapid weight loss itself is an independently well-established risk factor for gallstones regardless of method — it happens with bariatric surgery and aggressive dieting too. The medications may also directly affect gallbladder motility and bile composition, though that mechanism is less definitively established. The risk was notably higher in weight-loss trials, at higher doses, and with longer use.

What gallbladder symptoms should I watch for on a GLP-1?

Sudden, severe pain in the upper right abdomen — often after eating, especially fatty food — pain radiating to the back or shoulder, nausea or vomiting alongside the pain, and fever. Unlike routine GI side effects, these symptoms warrant prompt medical attention rather than waiting to see if they pass.

Should gallbladder risk stop me from taking a GLP-1?

For most people, no. Both meta-analyses found that while the risk increase is statistically significant, gallbladder disease remains a relatively uncommon event overall, and the 2025 analysis found GLP-1s reduced serious adverse events and mortality overall despite it. The most useful takeaway is knowing the specific warning signs and not dismissing upper right abdominal pain as routine GI discomfort.

Gallbladder disease and gallstones on a GLP-1

Gallbladder and biliary disease is one of the better-documented, more clinically significant risks associated with GLP-1 treatment — driven partly by the medication and partly by rapid weight loss itself.

Updated Jul 18, 2026

Of all the side effects tied to GLP-1 medications, gallbladder and biliary problems are among the best documented — and among the few worth treating as more than routine discomfort. Part of the risk comes from the medication itself and part from rapid weight loss, and the two compound each other. Here's what the evidence actually shows and which symptoms deserve a prompt call rather than a wait-and-see.

What the evidence shows

According to PubMed, a 2022 systematic review and meta-analysis of 76 randomized clinical trials involving over 103,000 patients found that GLP-1 receptor agonist use was associated with a significantly increased risk of gallbladder or biliary disease overall (relative risk 1.37), including specifically cholelithiasis (gallstones, RR 1.27), cholecystitis (gallbladder inflammation, RR 1.36), and broader biliary disease (RR 1.55) (He et al., JAMA Internal Medicine, 2022, DOI (external link)). A more recent, larger 2025 meta-analysis of nearly 100,000 patients confirmed this pattern, finding a 26% increase in gallbladder disorders with GLP-1 use, alongside broader cardiovascular benefits (Galli et al., JACC, 2025, DOI (external link)).

Why the risk is elevated

Two factors appear to drive this risk, and they compound each other:

Rapid weight loss itself is an independently well-established risk factor for gallstone formation, regardless of method — this happens with bariatric surgery and aggressive dieting too, not just GLP-1 medications.
The medications may have a direct effect on gallbladder motility and bile composition, separate from weight loss alone, though this mechanism is less definitively established than the weight-loss-driven pathway.

gallbladdercholelithiasisside-effectsrisk

Was this helpful?

Common questions

Questions people often ask about this topic.

Do GLP-1 medications increase the risk of gallstones?
Yes — this is one of the better-documented risks. A 2022 meta-analysis of 76 randomized trials with over 103,000 patients found GLP-1 use associated with a significantly increased risk of gallbladder or biliary disease overall (relative risk 1.37), including gallstones and gallbladder inflammation, and a larger 2025 meta-analysis confirmed the pattern with a 26% increase in gallbladder disorders.
Why does GLP-1 treatment raise gallbladder risk?
Two factors appear to drive it, and they compound each other. Rapid weight loss itself is an independently well-established risk factor for gallstones regardless of method — it happens with bariatric surgery and aggressive dieting too. The medications may also directly affect gallbladder motility and bile composition, though that mechanism is less definitively established. The risk was notably higher in weight-loss trials, at higher doses, and with longer use.
What gallbladder symptoms should I watch for on a GLP-1?
Sudden, severe pain in the upper right abdomen — often after eating, especially fatty food — pain radiating to the back or shoulder, nausea or vomiting alongside the pain, and fever. Unlike routine GI side effects, these symptoms warrant prompt medical attention rather than waiting to see if they pass.
Should gallbladder risk stop me from taking a GLP-1?
For most people, no. Both meta-analyses found that while the risk increase is statistically significant, gallbladder disease remains a relatively uncommon event overall, and the 2025 analysis found GLP-1s reduced serious adverse events and mortality overall despite it. The most useful takeaway is knowing the specific warning signs and not dismissing upper right abdominal pain as routine GI discomfort.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (external link)
JAMA Internal Medicine, 2022 · Peer-reviewed study
Meta-analysis of 76 RCTs (103,371 patients) finding significantly increased risk of gallbladder/biliary disease with GLP-1RA use, higher at higher doses, longer duration, and in weight-loss trials specifically.
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients

Improve this page

Gallbladder disease and gallstones on a GLP-1

What the evidence shows

Why the risk is elevated

Common questions

Evidence: For & Against

2Supporting

What symptoms to watch for

What this means practically

The bottom line

Related terms

Related guides